Dietary emu oil supplementation suppresses 5-fluorouracil chemotherapy-induced inflammation, osteoclast formation, and bone loss

American Journal of Physiology - Endocrinology and Metabolism

Volumn 302, Issue 11, 2012, Pages

  Nadhanan, Rethi Raghu ^a,b   Abimosleh, Suzanne M ^c   Su, Yu Wen ^a   Scherer, Michaela A ^a   Howarth, Gordon S ^b,c   Xian, Cory J ^a,b  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

^b UNIVERSITY OF ADELAIDE   (Australia)

^c WOMEN S AND CHILDREN S HOSPITAL   (Australia)

Author keywords

Anti inflammatory; Receptor activator of nuclear factor B ligand; Tumor necrosis factor

Indexed keywords

EMU OIL; FATTY ACID; FLUOROURACIL; RECEPTOR ACTIVATOR OF NUCLEAR FACTOR KAPPA B; SODIUM CHLORIDE; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG; WATER;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BONE DENSITY; CANCER CHEMOTHERAPY; CELL DENSITY; CONTROLLED STUDY; CYTOPATHOLOGY; DARK AGOUTI RAT; DIET SUPPLEMENTATION; EUTHANASIA; FEEDING; FEMALE; GENE EXPRESSION; HISTOPATHOLOGY; INFLAMMATION; METAPHYSIS; MOLECULAR BIOLOGY; NONHUMAN; OSTEOBLAST; OSTEOCLAST; OSTEOCLASTOGENESIS; OSTEOLYSIS; PRIORITY JOURNAL; RAT; TIBIA; TRABECULAR BONE; TREATMENT DURATION;

ANIMALS; ANTIMETABOLITES, ANTINEOPLASTIC; BONE AND BONES; BONE RESORPTION; CASEINS; DIET; DIETARY FATS, UNSATURATED; DIETARY SUPPLEMENTS; DROMAIIDAE; FATTY ACIDS; FEMALE; FLUOROURACIL; GROWTH PLATE; INFLAMMATION; OSTEOCLASTS; OSTEOGENESIS; RANK LIGAND; RATS; RATS, SPRAGUE-DAWLEY; REAL-TIME POLYMERASE CHAIN REACTION; RNA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84861890253     PISSN: 01931849     EISSN: 15221555     Source Type: Journal    
DOI: 10.1152/ajpendo.00587.2011     Document Type: Article

References (54)

1. Abimosleh SM, Lindsay RJ, Butler RN, Cummins AG, Howarth GS. Emu oil increases colonic crypt depth in a rat model of ulcerative colitis. Dig Dis Sci 57: 887-896, 2012.
2. Bennett DC, Code WE, Godin DV, Cheng KM. Comparison of the antioxidant properties of emu oil with other avian oils. Anim Prod Sci: 1345-1350, 2008.
3. Basu S, Michaelsson K, Olofsson H, Johansson S, Melhus H. Association between oxidative stress and bone mineral density. Biochem Biophys Res Commun 288: 275-279, 2001.
4. Beckerbauer LM, Thiel-Cooper R, Ahn DU, Sell JL, Parrish FC Jr, Beitz DC. Influence of two dietary fats on the composition of emu oil and meat. Poult Sci 80: 187-194, 2001.
5. Blijham GH. Chemotherapy of colorectal cancer. Anticancer Drugs 2: 233-245, 1991.
6. Boyle WJ, Simonet WS, Lacey DL. Osteoclast differentiation and activation. Nature 423: 337-342, 2003.
7. Bruning PF, Pit MJ, de Jong-Bakker M, van den Ende A, Hart A, van Enk A. Bone mineral density after adjuvant chemotherapy for premenopausal breast cancer. Br J Cancer 61: 308-310, 1990.
8. Byers RJ, Denton J, Hoyland JA, Freemont AJ. Differential patterns of osteoblast dysfunction in trabecular bone in patients with established osteoporosis. J Clin Pathol 50: 760-764, 1997.
9. Coleman RE. Risks and benefits of bisphosphonates. Br J Cancer 98: 1736-1740, 2008.
10. Conklin KA. Chemotherapy-associated oxidative stress: impact on chemotherapeutic effectiveness. Integr Cancer Ther 3: 294-300, 2004.
11. Darst M, Al-Hassani M, Li T, Yi Q, Travers JM, Lewis DA, Travers JB. Augmentation of chemotherapy-induced cytokine production by expression of the platelet-activating factor receptor in a human epithelial carcinoma cell line. J Immunol 172: 6330-6335, 2004.
12. Fan C, Cool JC, Scherer MA, Foster BK, Shandala T, Tapp H, Xian CJ. Damaging effects of chronic low-dose methotrexate usage on primary bone formation in young rats and potential protective effects of folinic acid supplementary treatment. Bone 44: 61-70, 2009.
13. Garrett IR, Boyce BF, Oreffo RO, Bonewald L, Poser J, Mundy GR. Oxygen-derived free radicals stimulate osteoclastic bone resorption in rodent bone in vitro and in vivo. J Clin Invest 85: 632-639, 1990.
14. Georgiou KR, Scherer MA, Fan CM, Cool JC, King TJ, Foster BK, Xian CJ. Methotrexate chemotherapy reduces osteogenesis but increases adipogenesis potential in the bone marrow. J Cell Physiol 227: 909-918, 2012.
15. Hemingway F, Taylor R, Knowles HJ, Athanasou NA. RANKLindependent human osteoclast formation with APRIL, BAFF, NGF, IGF I and IGF II. Bone 48: 938-944, 2011.
16. Hines SL, Mincey BA, Sloan JA, Thomas SP, Chottiner E, Loprinzi CL, Carlson MD, Atherton PJ, Salim M, Perez EA. Phase III randomized, placebo-controlled, double-blind trial of risedronate for the prevention of bone loss in premenopausal women undergoing chemotherapy for primary breast cancer. J Clin Oncol 27: 1047-1053, 2009.
17. Ing-Lorenzini K, Desmeules J, Plachta O, Suva D, Dayer P, Peter R. Low-energy femoral fractures associated with the long-term use of bisphosphonates: a case series from a Swiss university hospital. Drug Saf 32: 775-785, 2009.
18. Isomura H, Fujie K, Shibata K, Inoue N, Iizuka T, Takebe G, Takahashi K, Nishihira J, Izumi H, Sakamoto W. Bone metabolism and oxidative stress in postmenopausal rats with iron overload. Toxicology 197: 93-100, 2004.
19. Jiang X, Kalajzic Z, Maye P, Braut A, Bellizzi J, Mina M, Rowe DW. Histological analysis of GFP expression in murine bone. J Histochem Cytochem 53: 593-602, 2005.
20. Khosla S. Minireview: the OPG/RANKL/RANK system. Endocrinology 142: 5050-5055, 2001.
21. Kobayashi K, Takahashi N, Jimi E, Udagawa N, Takami M, Kotake S, Nakagawa N, Kinosaki M, Yamaguchi K, Shima N, Yasuda H, Morinaga T, Higashio K, Martin TJ, Suda T. Tumor necrosis factor alpha stimulates osteoclast differentiation by a mechanism independent of the ODF/RANKL-RANK interaction. J Exp Med 191: 275-286, 2000.
22. Kong YY, Feige U, Sarosi I, Bolon B, Tafuri A, Morony S, Capparelli C, Li J, Elliott R, McCabe S, Wong T, Campagnuolo G, Moran E, Bogoch ER, Van G, Nguyen LT, Ohashi PS, Lacey DL, Fish E, Boyle WJ, Penninger JM. Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand. Nature 402: 304-309, 1999.
23. Kremer JM, Lawrence DA, Petrillo GF, Litts LL, Mullaly PM, Rynes RI, Stocker RP, Parhami N, Greenstein NS, Fuchs BR, Mathur A, Robinson D, Spreling R, Biganouette J, et al. Effects of high-dose fish oil on rheumatoid arthritis after stopping nonsteroidal antiinflammatory drugs. Clinical and immune correlates. Arthritis Rheum 38: 1107-1114, 1995.
24. Lindsay RJ, Geier MS, Yazbeck R, Butler RN, Howarth GS. Orally administered emu oil decreases acute inflammation and alters selected small intestinal parameters in a rat model of mucositis. Br J Nutr 104: 513-519, 2010.
25. Linet MS, Ries LA, Smith MA, Tarone RE, Devesa SS. Cancer surveillance series: recent trends in childhood cancer incidence and mortality in the United States. J Natl Cancer Inst 91: 1051-1058, 1999.
26. Liu W, Saint DA. Validation of a quantitative method for real time PCR kinetics. Biochem Biophys Res Commun 294: 347-353, 2002.
27. Longley DB, Harkin DP, Johnston PG. 5-fluorouracil: mechanisms of action and clinical strategies. Nat Rev Cancer 3: 330-338, 2003.
28. Loo WT, Jin LJ, Cheung MN, Chow LW, Wang M. Combination of radiological and biochemical methods to assess bone mineral density of mandible in fully edentulous patients after chemotherapy: a 5-year prospective study. Expert Opin Investig Drugs 19, Suppl 1: S109-S115, 2010.
29. Maggio D, Barabani M, Pierandrei M, Polidori MC, Catani M, Mecocci P, Senin U, Pacifici R, Cherubini A. Marked decrease in plasma antioxidants in aged osteoporotic women: results of a cross-sectional study. J Clin Endocrinol Metab 88: 1523-1527, 2003.
30. Maruotti N, Grano M, Colucci S, d'Onofrio F, Cantatore FP. Osteoclastogenesis and arthritis. Clin Exp Med 11: 137-145, 2010.
31. Numazawa S, Sugihara K, Miyake S, Tomiyama H, Hida A, Hatsuno M, Yamamoto M, Yoshida T. Possible involvement of oxidative stress in 5-fluorouracil-mediated myelosuppression in mice. Basic Clin Pharmacol Toxicol 108: 40-45, 2011.
32. Oberlin O, Brugières L. [Osteoporosis and cancer in children and adolescents]. Arch Pediatr 16: 622-624, 2009.
33. Odvina CV, Zerwekh JE, Rao DS, Maalouf N, Gottschalk FA, Pak CY. Severely suppressed bone turnover: a potential complication of alendronate therapy. J Clin Endocrinol Metab 90: 1294-1301, 2005.
34. Paterson A, Baker T. Bisphosphonates and bone turnover in premenopausal women receiving adjuvant chemotherapy. J Clin Oncol 27: 1005-1006, 2009.
35. Pennica D, Nedwin GE, Hayflick JS, Seeburg PH, Derynck R, Palladino MA, Kohr WJ, Aggarwal BB, Goeddel DV. Human tumour necrosis factor: precursor structure, expression and homology to lymphotoxin. Nature 312: 724-729, 1984.
36. Peters GJ, van der Wilt CL, van Moorsel CJ, Kroep JR, Bergman AM, Ackland SP. Basis for effective combination cancer chemotherapy with antimetabolites. Pharmacol Ther 87: 227-253, 2000.
37. Pfeilschifter J, Chenu C, Bird A, Mundy GR, Roodman GD. Interleukin-1 and tumor necrosis factor stimulate the formation of human osteoclastlike cells in vitro. J Bone Miner Res 4: 113-118, 1989.
38. Pfeilschifter J, Diel IJ. Osteoporosis due to cancer treatment: pathogenesis and management. J Clin Oncol: 1570-1593, 2000.
39. Rahman MM, Bhattacharya A, Banu J, Fernandes G. Conjugated linoleic acid protects against age-associated bone loss in C57BL/6 female mice. J Nutr Biochem 18: 467-474, 2007.
40. Roodman GD, Kurihara N, Ohsaki Y, Kukita A, Hosking D, Demulder A, Smith JF, Singer FR. Interleukin 6. A potential autocrine/ paracrine factor in Paget's disease of bone. J Clin Invest 89: 46-52, 1992.
41. Sahin K, Sahin N, Kucuk O. Lycopene and chemotherapy toxicity. Nutr Cancer 62: 988-995, 2010.
42. Singh U, Jialal I. Anti-inflammatory effects of alpha-tocopherol. Ann NY Acad Sci 1031: 195-203, 2004.
43. Snowden JM, Whitehouse MW. Anti-inflammatory activity of emu oils in rats. Inflammopharmacology 5: 127-132, 1997.
44. Sun D, Krishnan A, Zaman K, Lawrence R, Bhattacharya A, Fernandes G. Dietary n-3 fatty acids decrease osteoclastogenesis and loss of bone mass in ovariectomized mice. J Bone Miner Res 18: 1206-1216, 2003.
45. Sylvester PW. Vitamin E and apoptosis. Vitam Horm 76: 329-356, 2007.
46. van der Sluis IM, van den Heuvel-Eibrink MM. Osteoporosis in children with cancer. Pediatr Blood Cancer 50: 474-478; discussion 486, 2008.
47. Whitehouse MW, Turner AG, Davis CK, Roberts MS. Emu oil(s): a source of non-toxic transdermal anti-inflammatory agents in aboriginal medicine. Inflammopharmacology 6: 1-8, 1998.
48. Xian CJ, Cool JC, Pyragius T, Foster BK. Damage and recovery of the bone growth mechanism in young rats following 5-fluorouracil acute chemotherapy. J Cell Biochem 99: 1688-1704, 2006.
49. Xian CJ, Cool JC, Scherer MA, Fan C, Foster BK. Folinic acid attenuates methotrexate chemotherapy-induced damages on bone growth mechanisms and pools of bone marrow stromal cells. J Cell Physiol 214: 777-785, 2008.
50. Xian CJ, Cool JC, Scherer MA, Macsai CE, Fan C, Covino M, Foster BK. Cellular mechanisms for methotrexate chemotherapy-induced bone growth defects. Bone 41: 842-850, 2007.
51. Xian CJ, Cool JC, van Gangelen J, Foster BK, Howarth GS. Effects of etoposide and cyclophosphamide acute chemotherapy on growth plate and metaphyseal bone in rats. Cancer Biol Ther 6: 170-177, 2007.
52. Xian CJ, Howarth GS, Cool JC, Foster BK. Effects of acute 5-fluorouracil chemotherapy and insulin-like growth factor-I pretreatment on growth plate cartilage and metaphyseal bone in rats. Bone 35: 739-749, 2004.
53. Yoganathan S, Nicolosi R, Wilson T, Handelman G, Scollin P, Tao R, Binford P, Orthoefer F. Antagonism of croton oil inflammation by topical emu oil in CD-1 mice. Lipids 38: 603-607, 2003.
54. Zhou FH, Foster BK, Sander G, Xian CJ. Expression of proinflammatory cytokines and growth factors at the injured growth plate cartilage in young rats. Bone 35: 1307-1315, 2004.